USOO9408801 B2 (12) United States Patent (10) Patent No.: US 9.408,801 B2 Florence et al. (45) Date of Patent: Aug. 9, 2016 (54) TOPICAL SKIN CARE FORMULATIONS (52) U.S. Cl. COMPRISING PLANT EXTRACTS CPC ................. A61K 8/97 (2013.01); A61 K8/0212 (2013.01); A61O 1704 (2013.01); A61O 19/00 (71) Applicant: MARY KAY, INC., Dallas, TX (US) (2013.01); A61O 19/008 (2013.01); A61O 19/02 (2013.01); A61O 19/08 (2013.01); A61 K (72) Inventors: Tiffany Florence, Dallas, TX (US); 2800/782 (2013.01) David Gan, Southlake, TX (US); (58) Field of Classification Search Michelle Hines, Hickory Creek, TX CPC ................................................ A61K 28OOf 782 (US) See application file for complete search history. (73) Assignee: Mary Kay Inc., Addison, TX (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 T.759.393--- B2 7, 2010 Joerger et al. ................. 514,546 U.S.C. 154(b) by 0 days. 2008/0044502 A1 2/2008 Wirth et al. ........ ... 424/757 2008/0227842 A1 9/2008 Krautler et al. ............... 514,414 (21) Appl. No.: 14/104,193 2009. O149420 A1 6/2009 Raederstorff et al. .......... 514/54 (22) Filed: Dec. 12, 2013 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data CN 101686728 A 3, 2010 JP 2001-187725 A 7, 2001 US 2014/OO99273 A1 Apr. 10, 2014 OTHER PUBLICATIONS O O International Search Report and Written Opinion issued in PCT Related U.S. Application Data Application No. PCT/US2012/034673, dated Nov. 26, 2012. (63) Continuation of application No. 13/888,068, filed on is Stig id in Chinese Application No. 20128.00224.58.6, May 6, 2013, now Pat. No. 8,636,989, which is a - continuation of application No. 13/453,690, filed on Primary Examiner — David J Blanchard Apr. 23, 2012, now Pat. No. 8,444.959. Assistant Examiner — Sarah Alawadi (60) Provisional application No. 61/477,812, filed on Apr. (74) Attorney, Agent, or Firm — Norton Rose Fulbright US 21, 2011. LLP (51) Int. Cl. (57) ABSTRACT A 6LX8/97 (2006.01) Disclosed is a topical skin composition and corresponding A61O 19/02 (2006.01) methods for its use that includes an extract from Bauhinia A61O 19/08 (2006.01) glauca, an extract from Rhodendron siderophyllum, and an A61O 1704 (2006.01) extract from Circidiphyllum japonicum. A61O 19/00 (2006.01) A6 IK 8/02 (2006.01) 18 Claims, 1 Drawing Sheet U.S. Patent Aug. 9, 2016 US 9.408,801 B2 Plant material (Powdered) — 8DO-OOOg 400 g 1. SOaked with 95%. EtOH, 1. SOaked Wit afia Standing Owerright at Ft. 2. Extracted under reflux for Extracted under reflux With 3 times (2 hr 1 hr 1 hr. CHCl3 for 4 times, each 1 hr. 3. COfCentrated u?er 3. COfCentrated Luder educed pressure educed preSSLIfe Extract (I) Extract with enriched alkaloids (I) 5g 5g ixed with 100ml HO Extracted with petroleum ether for 3 times, each 100 ml HO Part Petroleum ether extract(II) Extracted with CHCI for 3 times, each 100 ml HOPart CHCI Extract (III) Extracted with r-ELOH for 3 timeS, each 100 ml — HC part and emulsion n-BuOH Extract (IW) Filtered and lyophilized HO part (w US 9,408,801 B2 1. 2 TOPCAL SKIN CARE FORMULATIONS 0.001% to about 5% by weight of said extract from Tetracen COMPRISING PLANT EXTRACTS tron Sinense (ranges inside and out side of the stated range is also contemplated, e.g., 0.0001%, 6%, 7%, 8%, 9%, 10%, CROSS REFERENCE TO RELATED 15%, 20%, and more). The composition can further include a APPLICATIONS moisturization agent, an antioxidant, a structuring or thick ening agent, and/or an emulsifier (examples of each of these This application is a continuation of U.S. patent applica ingredients is provided below). The composition can further tion Ser. No. 13/888,068 filed May 6, 2013, which is a con include a silicone containing compound and/or a Sunscreen tinuation of U.S. patent application Ser. No. 13/453,690, filed agent (examples of these ingredients are also provided Apr. 23, 2012, which claims the benefit of U.S. Provisional 10 below). The extracts can be aqueous extracts, alcoholic Application No. 61/477,812, filed Apr. 21, 2011. The con extracts, glycolic extracts, or oil extracts. In particular tents of the referenced applications are incorporated into the instances, the extracts are aqueous extracts. The extracts can present application by reference. each be obtained from the whole plant of Burretiodendron hsiennu, Bauhinia brachycarpa var. Cavaleriei, and Tetra BACKGROUND OF THE INVENTION 15 centron sinense, or from any part of the plant thereof (e.g., root, stem, leaf flower, seed) at the exclusion of other parts of A. Field of the Invention the plant. In particular instances, the extracts are aqueous The present invention relates generally to compositions extracts from the whole plants, respectively. The composition that include one or any combination of plant extracts to treat can be formulated as a cleanser product, a toner product, a a variety of skin conditions. The extracts can be included in moisturizer product, or a mask product. Additionally, each of topical skin compositions, edible compositions, injectible the MMP-1 inhibitors can also have further functionalities compositions, oral compositions, hair care compositions, etc. that can be beneficial to skin. For instance, the first MMP-1 B. Description of Related Art inhibitor can also be an antioxidant, a lipoxygenase inhibitor, Ageing, chronic exposure to adverse environmental fac and a tyrosinase inhibitor. The second MMP-1 inhibitor can tors, malnutrition, fatigue, etc., can change the visual appear 25 also be an antioxidant and a lipoxygenase inhibitor. The third ance, physical properties, or physiological functions of skin MMP-1 inhibitor can also be an antioxidant. Further, the in ways that are considered visually undesirable. The most combined extracts can be used to treat a variety of skin con notable and obvious changes include the development of fine ditions by applying a composition having said extracts to skin lines and wrinkles, loss of elasticity, increased sagging, loss in need of Such treatment. As indicated above, the composi of firmness, loss of color evenness or tone, coarse Surface 30 tion can be effective in inhibiting MMP-1 activity in skin, texture, and mottled pigmentation. Less obvious, but measur which can aid in reducing the appearance of fine lines and able changes which occur as skin ages or endures chronic wrinkles, sagging skin, loose skin, and/or skin that has an environmental insult include a general reduction in cellular overall aged appearance. The composition can also inhibit and tissue vitality, reduction in cell replication rates, reduced lipoxygenase activity, which can further aid in the skin treat cutaneous blood flow, reduced moisture content, accumu 35 ment process while having an added benefit of reducing lated errors in structure and function, alterations in the normal sebum production in skin cells, thereby treating the appear regulation of common biochemical pathways, and a reduction ance of oily skin. The composition can also inhibit tyrosinase in the skins ability to remodel and repair itself. Many of the activity, which is a key enzyme in the pathway for producing alterations in appearance and function of the skin are caused melanin. This can be used to reduce the appearance of hyper by changes in the outer epidermal layer of the skin, while 40 pigmented skin, Sun spots, aged spots, liver spots, melasma, others are caused by changes in the lower dermis. and/or uneven skintone. Further, the composition can be used Previous attempts to improve the visual appearance of skin to reduce oxidative damage in skin cells, which can provide with known skin active-ingredients have been shown to have both a treatment and protection function from reactive oxy various drawbacks such as skin irritation and prolonged gen species and the like. Also, the composition can be a recovery periods. 45 leave-on or rinse of composition. In another instance, the inventors discovered that a combi SUMMARY OF THE INVENTION nation of extracts from Circidiphyllum japonicum, Bauhinia glauca, and Rhododendron siderophyllum can be used to The inventors discovered that particular sets of ingredients inhibit lipoxygenase activity in skin. In this regard, there is can be used to treat certain skin conditions ranging from fine 50 disclosed a topical skin composition comprising a first lines or wrinkles, oily skin or excessive sebum production, lipoxygenase inhibitor, wherein said first inhibitor can be an and skin having dark spots (e.g., liver spots, age spots, etc.), extract from Circidiphyllum japonicum, a second lipoxyge melasma, hyperpigmentation, and uneven skin tone. nase inhibitor, wherein said second inhibitor can be an extract In one instance, for example, there is disclosed a topical from Bauhinia glauca, and a third lipoxygenase inhibitor, skin composition comprising a first MMP-1 inhibitor, 55 wherein said third inhibitor can be an extract from Rhodo wherein said first inhibitor can be an extract from Burretio dendron siderophyllum. The composition can take the form of dendron hsiennu, a second MMP-1 inhibitor, wherein said an emulsion (e.g., W/o, O?w, W/si, si/w, whofw, Wisi/w, of w/o. second inhibitor can be an extract from Bauhinia brachy si/w/si) a cream, a lotion, a solution, an anhydrous stick, a carpa var. Cavaleriei, and a third MMP-1 inhibitor, wherein serum, etc. The composition can include from about 0.001% said third inhibitor can be an extract from Tetracentron sin 60 to about 5% by weight of said extract from Circidiphyllum ense. The composition can take the form of an emulsion (e.g., japonicum, from about 0.001% to about 5% by weight of said w/o.